Core Insights - Humana Inc. (HUM) is expected to report second-quarter 2025 results on July 30, with earnings estimated at $6.32 per share and revenues at $31.78 billion, reflecting an 8.2% year-over-year growth in revenues despite a 9.2% decline in earnings [2][6] Financial Performance Expectations - The full-year 2025 revenue estimate for Humana is $126.1 billion, indicating a 7.6% year-over-year increase, while the EPS for the current year is projected at $16.37, showing a 1% gain year-over-year [3] - Humana has consistently beaten earnings estimates in the past four quarters, with an average surprise of 14.3% [3] Earnings Prediction Model - The company has a positive Earnings ESP of +10.51% and a Zacks Rank of 3 (Hold), suggesting a likelihood of an earnings beat this quarter [4] Revenue and Income Growth - The consensus estimate for second-quarter premiums indicates a 7.4% increase year-over-year, with total Medicare expected to grow by 3.8% [7] - Operating income from the Insurance unit is projected to grow by 21.4% compared to the previous year, contributing positively to earnings [8] Cost and Membership Challenges - The CenterWell unit is expected to see a 0.4% decline in operating income, and investment income is projected to drop nearly 9% year-over-year [9] - Total operating costs are anticipated to exceed $30 billion, increasing by more than 5%, which may negatively impact the bottom line [9] - The overall benefits expense ratio is expected to worsen to 89.47%, and insurance membership is projected to decline by 5.8% year-over-year [10] Peer Performance Comparison - Centene Corporation reported a second-quarter adjusted loss per share of 16 cents, missing estimates due to rising medical costs and declining service revenues [11] - Molina Healthcare reported adjusted EPS of $5.48, slightly missing estimates due to higher medical care costs [12] - Elevance Health reported adjusted EPS of $8.84, also missing estimates due to rising medical costs, despite some offset from increasing premiums [12]

Financial Performance & Valuation - UnitedHealth's earnings starting point this year is expected to be in the $18-20 range per share [6][7] - Raymond James estimates UnitedHealth could potentially claw back to $30 per share of earnings in a couple of years, but the stock is considered 30-40% more expensive than similar stories [5] - Medicare Advantage is now considered a 1-2% margin business [10][12] - Other health insurers like Humana (6 PE) and CVS (8 PE) are considered cheaper ways to play the recovery in Medicare Advantage [5] - Elevance is trading under 10 times earnings, making it a potentially more attractive valuation [7] Business Strategy & Challenges - UnitedHealth has an opportunity to reset its strategy, particularly regarding its $60 billion Optimum Health business, where it takes risk for itself and competitors [9] - The company needs to reassess whether taking risk for competitors like Humana in Medicare Advantage, and potentially losing money, makes sense [10] - An ongoing investigation could lead to behavior changes, such as less aggressive coding and less stringent prior authorizations, which could impact earnings in the 1-2% margin Medicare Advantage business [12] Market Dynamics & Competitive Landscape - UnitedHealth has a diversified franchise across different lines of business, including a strong commercial franchise and Optimum business [2] - Other insurers like Cigna, with less government exposure, are preferred by some [7]

Company Overview - Humana (HUM) is expected to report a year-over-year decline in earnings of 9.2%, with an estimated EPS of $6.32 for the quarter ended June 2025, while revenues are projected to increase by 8.2% to $31.78 billion [3][12] - The earnings report is scheduled for release on July 30, and the actual results will significantly influence the stock price depending on whether they meet or exceed expectations [2][12] Earnings Estimates and Trends - The consensus EPS estimate has been revised down by 0.14% over the last 30 days, indicating a slight reassessment by analysts [4] - Humana's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +10.51%, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Humana exceeded the expected EPS of $9.98 by delivering $11.58, resulting in a surprise of +16.03% [13] - Over the past four quarters, Humana has consistently beaten consensus EPS estimates [14] Industry Context - UnitedHealth Group (UNH), another player in the Zacks Medical - HMOs industry, is expected to report a year-over-year EPS decline of 27.4%, with revenues projected at $111.6 billion, up 12.9% [18] - UnitedHealth's consensus EPS estimate has been revised down by 4.5% in the last 30 days, leading to a negative Earnings ESP of -13.1%, combined with a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [19]

Core Insights - Humana Inc. is accelerating efforts to streamline prior authorization processes to enhance care request approvals and reduce administrative burdens for physicians [1][3] - The company aims to improve the healthcare system's complexity and navigation challenges as highlighted by its CEO [2] Group 1: Prior Authorization Reforms - Humana plans to reduce prior authorization requirements by approximately one-third for outpatient services by January 1, 2026 [6] - The company will eliminate authorization requirements for specific diagnostic services, including colonoscopies and certain imaging tests [6] - By 2026, Humana aims to provide decisions within one business day for at least 95% of complete electronic prior authorization requests, improving from over 85% currently [6] Group 2: Transparency and Reporting - Starting in 2026, Humana will publicly report prior authorization metrics, including approval and denial rates, as well as average decision times [3] - The company is working to expedite the implementation of new federal transparency requirements related to prior authorization [3] Group 3: Legal and Financial Implications - A recent court ruling upheld the government's decision to downgrade Humana's Medicare quality ratings, which may impact future Medicare bonus payments starting in 2026 [4] - Despite a reported decline in Humana's denial rates, the overall industry has experienced higher rejection rates [4] Group 4: Stock Performance - Humana's stock price increased by 3.18% to $230.53, although it is trading near its 52-week low of $206.87 [5]

We're about 2 minutes away from the end of the trading day. Scarlet Fu and Vonnie Quinn here with you and here to help take you through the closing bell. We've got a global simulcast.Tim Sandvik joins us as well as Israeli lee. We bring together our Bloomberg Television, radio and you tube audiences worldwide as we pass through the most crucial moments of the trading day. And Tim, it doesn't look like a whole lot is going on when you look at the closing numbers here in the S&P 500, little change, but it's b ...

Humana lost its lawsuit seeking to reverse cuts to its Medicare bonus payments, a blow for the insurer that had hoped the court would restore billions in revenue https://t.co/ODzGjwKMcT ...

Core Viewpoint - Humana Inc. is currently consolidating but may soon reverse and rally due to being oversold and approaching a support level, indicating bullish dynamics [1]. Group 1: Stock Dynamics - A stock typically remains within its usual trading range, and when it is pushed below this range by aggressive sellers, it is considered oversold [2]. - The concept of reversion to the mean suggests that oversold stocks often attract buyers who expect a price increase, potentially leading to a self-fulfilling prophecy [2]. Group 2: Indicators and Support Levels - The stochastic indicator is commonly used to determine if a stock is oversold, with lower red and blue lines indicating such conditions, which is currently the case for Humana [4]. - Humana is nearing a previously established support level, which could be bullish as remorseful sellers may place buy orders if the stock returns to this price [5]. - A significant number of buy orders at the support level could reinforce this support, creating a favorable environment for a price increase [6].

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving ...

Medicare Advantage Strategy - Humana's core business is Medicare Advantage (MA), which remains an attractive sector[22, 35, 36] - The company focuses on delivering a more stable and compelling MA margin through clinical excellence and operating leverage[22] - Humana aims for a 3%+ Individual Medicare Advantage pre-tax margin[31, 55, 56] - Sustained growth in Medicare Advantage depends on superior customer satisfaction and retention[100] CenterWell and Medicaid Growth - Humana will continue to allocate capital to CenterWell and Medicaid, viewing them as strategic growth engines[22, 33] - CenterWell Primary Care is on track to reach approximately $6 billion in revenue with over 440,000-460,000 patients in 2025, with wholly-owned centers demonstrating a 32% CAGR in average contribution margin from 2021 to 2024[141, 145] - Humana expects to improve Medicaid pre-tax margin by 200-300 bps as its Medicaid presence matures[215] Financial Performance and Operating Leverage - Humana expects adjusted operating expenses to grow at less than half the rate of revenue through 2028, inclusive of investments[189] - The company anticipates a 150-180 bps improvement in operating leverage by 2028, with over 50% driven by cost reduction[199, 200] - Humana projects a 6-8% CAGR in Individual Medicare Advantage PMPM Underwriting Margin from 2025E to 2028E[209, 210]

Humana (HUM) 2025 Investor Day Summary Company Overview - **Company**: Humana Inc. (HUM) - **Event**: 2025 Investor Day held on June 16, 2025, in Louisville, Kentucky Key Industry Insights - **Industry Focus**: Senior healthcare services, particularly Medicare Advantage (MA) - **Market Dynamics**: The Medicare Advantage sector is experiencing significant growth, with over 10,000 individuals turning 65 daily, leading to an expected increase in Medicare beneficiaries from 64 million today to 72 million by 2030 [88][90] Core Points and Arguments 1. **Transformation from Insurance to Health Services**: Humana has evolved from primarily a health insurance company to a health services company, with a focus on integrated senior healthcare strategies [19][20] 2. **Medicare Advantage Value Proposition**: - MA delivers superior value and better health outcomes compared to original Medicare [80] - MA reduces out-of-pocket costs for seniors, providing comprehensive benefits such as dental, vision, and pharmacy [83][84] - MA has bipartisan political support, with over half of Medicare beneficiaries enrolled in MA plans [87] 3. **Financial Performance and Growth**: - Humana aims to unlock significant earnings power, currently operating at a fraction of its potential [22] - The company is focused on delivering a stable and compelling Medicare Advantage margin, emphasizing operational efficiency over benefits [68][69] - Humana's enrollment CAGR has been 11%, outpacing the industry average of 9% [98] 4. **Clinical Excellence Strategy**: - The strategy is built on understanding member needs, improving health outcomes, and lowering total care costs [102] - Emphasis on accurate diagnosis, follow-up care, and innovative clinical programs to enhance member engagement and trust [102][103] 5. **Operational Leverage**: - Humana is focused on improving operational efficiency to drive better margins and sustainable growth [40][41] - The company plans to invest in clinical outcomes and lower medical costs while narrowing the gap in operational leverage [41][42] Additional Important Insights - **Challenges and Opportunities**: The current environment presents challenges, but these can also create opportunities for growth and innovation [75][76] - **Future Projections**: Humana anticipates that by 2028, Medicaid and Cinerwell will play a more prominent role in the business, contributing to overall growth [66][68] - **Member Retention Focus**: The company recognizes that retaining existing members is crucial for long-term growth, with service quality being a key factor in retention [51][52] Conclusion - Humana is positioning itself as a leader in the senior healthcare services market, with a strong focus on Medicare Advantage, clinical excellence, and operational efficiency. The company aims to leverage its scale and market presence to drive sustainable growth and deliver better health outcomes for its members while enhancing shareholder value [97][98]